Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

Peer Review reports

Original Submission
1 Apr 2022	Submitted	Original manuscript
23 Apr 2022	Reviewed	Reviewer Report
29 Apr 2022	Reviewed	Reviewer Report
15 Jun 2022	Author responded	Author comments - Rohan Medhekar
Resubmission - Version 2
15 Jun 2022	Submitted	Manuscript version 2
27 Jul 2022	Reviewed	Reviewer Report
31 Jul 2022	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
2 Aug 2022	Editorially accepted
18 Aug 2022	Article published	10.1186/s12885-022-09980-9

Back to article page